Immunotherapy in NSCLC Patients with Brain Metastases

被引：21

作者：

Buriolla, Silvia ^{[1
]}

Pelizzari, Giacomo ^{[2
]}

Corvaja, Carla ^{[1
]}

Alberti, Martina ^{[1
]}

Targato, Giada ^{[1
]}

Bortolot, Martina ^{[1
]}

Torresan, Sara ^{[1
]}

Cortiula, Francesco ^{[2
]}

Fasola, Gianpiero ^{[2
]}

Follador, Alessandro ^{[2
]}

机构：

[1] Univ Udine, Dept Med DAME, I-33100 Udine, Italy

[2] Azienda Sanitaria Univ Friuli Cent ASUFC, Dept Oncol, I-33100 Udine, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 13期

关键词：

NSCLC; immunotherapy; brain; metastases; CELL LUNG-CANCER; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; 1ST-LINE TREATMENT; POOLED ANALYSIS; ITALIAN COHORT; PEMBROLIZUMAB; CHEMOTHERAPY; BLOCKADE; MELANOMA;

D O I：

10.3390/ijms23137068

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases (BMs) during their disease, with considerable morbidity and mortality. The management of BMs in patients with NSCLC is a clinical challenge and requires a multidisciplinary approach to gain effective intracranial disease control. Over the last decade, immune checkpoint inhibitors (ICIs) have emerged as a game-changer in the treatment landscape of advanced NSCLC, with significant improvements in survival outcomes, although patients with BMs are mostly underrepresented in randomized clinical trials. Moreover, the safety and activity of ICIs and radiotherapy combinations compared with single-agent or sequential modalities is still under evaluation to establish the optimal management of these patients. The aim of this review is to summarize the state-of-the-art of clinical evidence of ICIs intracranial activity and the main challenges of incorporating these agents in the treatment armamentarium of NSCLC patients with BMs.

引用

页数：12

共 76 条

[41] Modern Radiation Therapy for the Management of Brain Metastases From Non-Small Cell Lung Cancer: Current Approaches and Future Directions [J].

Mantovani, Cristina ;

Gastino, Alessio ;

Cerrato, Marzia ;

Badellino, Serena ;

Ricardi, Umberto ;

Levis, Mario .

FRONTIERS IN ONCOLOGY, 2021, 11

[42] Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial [J].

Margolin, Kim ;

Ernstoff, Marc S. ;

Hamid, Omid ;

Lawrence, Donald ;

McDermott, David ;

Puzanov, Igor ;

Wolchok, Jedd D. ;

Clark, Joseph I. ;

Sznol, Mario ;

Logan, Theodore F. ;

Richards, Jon ;

Michener, Tracy ;

Balogh, Agnes ;

Heller, Kevin N. ;

Hodi, F. Stephen .

LANCET ONCOLOGY, 2012, 13 (05) :459-465

[43] Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients [J].

Martino, E. C. ;

Misso, G. ;

Pastina, P. ;

Costantini, S. ;

Vanni, F. ;

Gandolfo, C. ;

Botta, C. ;

Capone, F. ;

Lombardi, A. ;

Pirtoli, L. ;

Tassone, P. ;

Ulivieri, C. ;

Tagliaferri, P. ;

Cusi, M. G. ;

Caraglia, M. ;

Correale, P. .

CELL DEATH DISCOVERY, 2016, 2

[44] Combining chemotherapy with PD-1 blockade in NSCLC [J].

Mathew, Matthen ;

Enzler, Thomas ;

Shu, Catherine A. ;

Rizvi, Naiyer A. .

PHARMACOLOGY & THERAPEUTICS, 2018, 186 :130-137

[45] Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J].

Mok, Tony S. K. ;

Wu, Yi-Long ;

Kudaba, Iveta ;

Kowalski, Dariusz M. ;

Cho, Byoung Chul ;

Turna, Hande Z. ;

Castro, Gilberto, Jr. ;

Srimuninnimit, Vichien ;

Laktionov, Konstantin K. ;

Bondarenko, Igor ;

Kubota, Kaoru ;

Lubiniecki, Gregory M. ;

Zhang, Jin ;

Kush, Debra ;

Lopes, Gilberto .

LANCET, 2019, 393 (10183) :1819-1830

[46]

Nadal E, 2021, J THORAC ONCOL, V16, pS863

[47] Epidemiology of Brain Metastases [J].

Nayak, Lakshmi ;

Lee, Eudocia Quant ;

Wen, Patrick Y. .

CURRENT ONCOLOGY REPORTS, 2012, 14 (01) :48-54

[48] Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Novello, S. ;

Barlesi, F. ;

Califano, R. ;

Cufer, T. ;

Ekman, S. ;

Levra, M. Giaj ;

Kerr, K. ;

Popat, S. ;

Reck, M. ;

Senan, S. ;

Simo, G. V. ;

Vansteenkiste, J. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2016, 27 :v1-v27

[49] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer [J].

Paz-Ares, L. ;

Luft, A. ;

Vicente, D. ;

Tafreshi, A. ;

Gumus, M. ;

Mazieres, J. ;

Hermes, B. ;

Senler, F. Cay ;

Csoszi, T. ;

Fulop, A. ;

Rodriguez-Cid, J. ;

Wilson, J. ;

Sugawara, S. ;

Kato, T. ;

Lee, K. H. ;

Cheng, Y. ;

Novello, S. ;

Halmos, B. ;

Li, X. ;

Lubiniecki, G. M. ;

Piperdi, B. ;

Kowalski, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2040-2051

[50] First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [J].

Paz-Ares, Luis ;

Ciuleanu, Tudor-Eliade ;

Cobo, Manuel ;

Schenker, Michael ;

Zurawski, Bogdan ;

Menezes, Juliana ;

Richardet, Eduardo ;

Bennouna, Jaafar ;

Felip, Enriqueta ;

Juan-Vidal, Oscar ;

Alexandru, Aurelia ;

Sakai, Hiroshi ;

Lingua, Alejo ;

Salman, Pamela ;

Souquet, Pierre-Jean ;

De Marchi, Pedro ;

Martin, Claudio ;

Perol, Maurice ;

Scherpereel, Arnaud ;

Lu, Shue ;

John, Thomas ;

Carbone, David P. ;

Meadows-Shropshire, Stephanie ;

Agrawal, Shruti ;

Oukessou, Abderrahim ;

Yan, Jinchun ;

Reck, Martin .

LANCET ONCOLOGY, 2021, 22 (02) :198-211

← 1 2 3 4 5 6 7 8 →